Skip to content

Study · In vitro (cells) · 2011

5 results

NAD+ treatment decreases tumor cell survival by inducing oxidative stress.

Zhao C, Hong Y, Han J, Ma Y, Chen H, Xia W, Ying W

Frontiers in bioscience (Elite edition)1 Jan 2011Cited by 12 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In tumor cells including C6 glioma cells, NAD at 10 micromolar to 1 mM significantly decreased survival.

    In plain wordsIn cells, NAD at 10 micromolar to 1 mM decreased tumor cell survival.

    Outcome
    DecreaseTumor cell survival
    Study

    n: not reported in source

    Tumor cells including C6 glioma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10 micromolar to 1 mMAs given in this study.

    Source sentences

    Summary
    In this study we found that treatment of NAD+ at concentrations from 10 micromolar to 1 mM can significantly decrease the survival of various types of tumor cells such as C6 glioma cells.
  2. 02LabIn vitro (cells)Safety outcome

    In primary astrocyte cultures, NAD did not impair survival.

    In plain wordsIn cells, NAD did not impair primary astrocyte survival.

    Outcome
    No significant changePrimary astrocyte survival
    Study

    n: not reported in source

    Primary astrocyte cultures
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, NAD+ treatment did not impair the survival of primary astrocyte cultures.
  3. 03LabIn vitro (cells)Mechanism

    In tumor cells, oxidative stress mediated the effects of NAD on survival.

    In plain wordsIn cells, oxidative stress mediated the effects of NAD on tumor cell survival.

    Outcome
    Not applicableOxidative stress mediation
    Study

    n: not reported in source

    Tumor cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our study has also indicated that oxidative stress mediates the effects of NAD+ on the survival of tumor cells, and P2X7 receptors and altered calcium homeostasis are involved in the effects of NAD+ on the cell survival.
  4. 04LabIn vitro (cells)Mechanism

    In tumor cells, P2X7 receptors were involved in the effects of NAD on survival.

    In plain wordsIn cells, P2X7 receptors contributed to the effects of NAD on tumor cell survival.

    Outcome
    Not applicableP2X7 receptor involvement
    Study

    n: not reported in source

    Tumor cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our study has also indicated that oxidative stress mediates the effects of NAD+ on the survival of tumor cells, and P2X7 receptors and altered calcium homeostasis are involved in the effects of NAD+ on the cell survival.
  5. 05LabIn vitro (cells)Mechanism

    In tumor cells, altered calcium homeostasis was involved in the effects of NAD on survival.

    In plain wordsIn cells, altered calcium homeostasis contributed to the effects of NAD on tumor cell survival.

    Outcome
    Not applicableCalcium homeostasis involvement
    Study

    n: not reported in source

    Tumor cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our study has also indicated that oxidative stress mediates the effects of NAD+ on the survival of tumor cells, and P2X7 receptors and altered calcium homeostasis are involved in the effects of NAD+ on the cell survival.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.